IL-17A produced by invariant natural killer T cells and CD3+ CD56+ αGalcer-CD1d tetramer- T cells promote liver fibrosis in patients with primary biliary cholangitis

J Leukoc Biol. 2022 Nov;112(5):1079-1087. doi: 10.1002/JLB.2A0622-586RRRR. Epub 2022 Jun 22.

Abstract

Primary biliary cholangitis (PBC) is characterized as interlobular bile duct injury and fibrosis, which results from the loss of tolerance to self-antigens. However, the exact pathologic mechanism leading to injury and fibrosis in PBC patients is not fully understood. Therefore, in this study, we examined the role of the T cell subsets in PBC patients and healthy controls (HCs). A higher number of invariant Natual killer T (iNKT) cells as well as CD3+ CD56+ αGalcer-CD1d tetramer- T cells were found in patients with PBC compared with HCs. Moreover, these 2 T subpopulations produced significantly higher levels of Interleukin (IL)-17A in PBC patients than those in in HCs, which has also been positively correlated with the disease severity. Furthermore, the level of IL-17A produced by these 2 subpopulations was increased after stimulation of the autoantibodies in patients with PBC. Also, the elevated IL-17A levels promoted the PBC-related fibrosis, thus presenting a change in frequencies and functions of these cell phenotypes in the deterioration of the duct damage-related fibrosis. This study clarified PBC patients' distinct T subpopulations characteristics, providing evidence-based diagnostic and therapies for these patients. The correlation between unclassical T subsets and IL-17A may provide a novel target for the immunotherapy of PBC.

Keywords: IL-17A; NKT cells; fibrosis; primary biliary cholangitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD1d
  • Autoantibodies
  • Autoantigens
  • Fibrosis
  • Humans
  • Interleukin-17
  • Liver Cirrhosis
  • Liver Cirrhosis, Biliary*
  • Natural Killer T-Cells*

Substances

  • Interleukin-17
  • Autoantigens
  • Autoantibodies
  • CD1D protein, human
  • Antigens, CD1d